Risk factors and outcome of COVID-19 in patients with hematological malignancies (2024)

Piñana, J. L., Martino Bofarull, R., García-García, I., Parody Porras, R., Morales, M. D., Benzo, G., Gómez-Catalan, I., Coll, R., De La Fuente, I., Luna, A., Merchán, B., Chinea, A., De Miguel, D., Serrano, A., Pérez, C., Diaz, C., Lopez, J. L., Saez, A. J., Bailén, R., ... Sureda, A. (2020). Risk factors and outcome of COVID-19 in patients with hematological malignancies. Experimental Hematology & Oncology, 9(1). https://doi.org/10.1186/s40164-020-00177-z

Piñana, José Luis ; Martino Bofarull, Rodrigo ; García-García, Irene et al. / Risk factors and outcome of COVID-19 in patients with hematological malignancies. In: Experimental Hematology & Oncology. 2020 ; Vol. 9, Núm. 1.

@article{3ebe52854fc9471697d0fddc10761e4b,

title = "Risk factors and outcome of COVID-19 in patients with hematological malignancies",

abstract = "Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1). Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.",

keywords = "COVID-19",

author = "Pi{\~n}ana, {Jos{\'e} Luis} and {Martino Bofarull}, Rodrigo and Irene Garc{\'i}a-Garc{\'i}a and {Parody Porras}, Roc{\'i}o and Morales, {Mar{\'i}a Dolores} and Gonzalo Benzo and Irene G{\'o}mez-Catalan and Rosa Coll and {De La Fuente}, Ignacio and Alejandro Luna and Beatriz Merch{\'a}n and Anabelle Chinea and {De Miguel}, Dunia and Ana Serrano and Carmen P{\'e}rez and Carola Diaz and Lopez, {Jos{\'e} Luis} and Saez, {Adolfo Jes{\'u}s} and Rebeca Bail{\'e}n and Teresa Zudaire and Diana Mart{\'i}nez and Manuel Jurado and Maria Calbacho and Lourdes V{\'a}zquez and {Garcia Cadenas}, Irene and Fox, {Maria Laura} and Pimentel, {Ana I.} and Guiomar Bautista and Agust{\'i}n Nieto and Pascual Fernandez and Vallejo, {Juan Carlos} and Carlos Solano and Marta Valero and Ildefonso Espigado and Raquel Salda{\~n}a and Luisa Sisinni and Jose-Maria Ribera and Jim{\'e}nez, {Mar{\'i}a Jos{\'e}} and {Trabazo del Castillo}, Mar{\'i}a and {Gonz{\'a}lez Vicent}, Marta and Noem{\'i} Fern{\'a}ndez and Carme Talarn and Montoya, {Maria Carmen} and Angel Cedillo and Anna Sureda",

year = "2020",

doi = "10.1186/s40164-020-00177-z",

language = "English",

volume = "9",

number = "1",

}

Risk factors and outcome of COVID-19 in patients with hematological malignancies. / Piñana, José Luis; Martino Bofarull, Rodrigo; García-García, Irene et al.
In: Experimental Hematology & Oncology, Vol. 9, Núm. 1, 2020.

Producció científica: Contribució a una revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Risk factors and outcome of COVID-19 in patients with hematological malignancies

AU - Piñana, José Luis

AU - Martino Bofarull, Rodrigo

AU - García-García, Irene

AU - Parody Porras, Rocío

AU - Morales, María Dolores

AU - Benzo, Gonzalo

AU - Gómez-Catalan, Irene

AU - Coll, Rosa

AU - De La Fuente, Ignacio

AU - Luna, Alejandro

AU - Merchán, Beatriz

AU - Chinea, Anabelle

AU - De Miguel, Dunia

AU - Serrano, Ana

AU - Pérez, Carmen

AU - Diaz, Carola

AU - Lopez, José Luis

AU - Saez, Adolfo Jesús

AU - Bailén, Rebeca

AU - Zudaire, Teresa

AU - Martínez, Diana

AU - Jurado, Manuel

AU - Calbacho, Maria

AU - Vázquez, Lourdes

AU - Garcia Cadenas, Irene

AU - Fox, Maria Laura

AU - Pimentel, Ana I.

AU - Bautista, Guiomar

AU - Nieto, Agustín

AU - Fernandez, Pascual

AU - Vallejo, Juan Carlos

AU - Solano, Carlos

AU - Valero, Marta

AU - Espigado, Ildefonso

AU - Saldaña, Raquel

AU - Sisinni, Luisa

AU - Ribera, Jose-Maria

AU - Jiménez, María José

AU - Trabazo del Castillo, María

AU - González Vicent, Marta

AU - Fernández, Noemí

AU - Talarn, Carme

AU - Montoya, Maria Carmen

AU - Cedillo, Angel

AU - Sureda, Anna

PY - 2020

Y1 - 2020

N2 - Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1). Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.

AB - Background: Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods: This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results: We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1-93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2-3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6-5.2, p < 0.0001); ECOG 3-4 (OR, 2.56, 95% CI 1.4-4.7, p = 0.003); neutropenia (< 0.5 × 109/L) (OR 2.8, 95% CI 1.3-6.1, p = 0.01); and a C-reactive protein (CRP) > 20 mg/dL (OR 3.3, 95% CI 1.7-6.4, p < 0.0001). In multivariate analysis of 216 patients with very severe COVID-19, treatment with azithromycin or low dose corticosteroids was associated with lower OM (OR 0.42, 95% CI 0.2-0.89 and OR 0.31, 95% CI 0.11-0.87, respectively, p = 0.02) whereas the use of hidroxycloroquine did not show significant improvement in OM (OR 0.64, 95% CI 0.37-1.1, P = 0.1). Conclusions: In most patients with hematological malignancies COVID-19 mortality was directly driven by older age, disease status, performance status, as well as by immune (neutropenia) parameters and level of inflammation (high CRP). Use of azithromycin and low dose corticosteroids may be of value in very severe COVID-19.

KW - COVID-19

U2 - 10.1186/s40164-020-00177-z

DO - 10.1186/s40164-020-00177-z

M3 - Article

C2 - 32864192

SN - 2162-3619

VL - 9

JO - Experimental Hematology & Oncology

JF - Experimental Hematology & Oncology

IS - 1

ER -

Piñana JL, Martino Bofarull R, García-García I, Parody Porras R, Morales MD, Benzo G et al. Risk factors and outcome of COVID-19 in patients with hematological malignancies. Experimental Hematology & Oncology. 2020;9(1). doi: 10.1186/s40164-020-00177-z